Vidaza IV Granted Priority Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharmion's NDA supplement for IV administration of its demethylating agent Vidaza (azacitidine) has a Sept. 29 user fee date under a six-month review, the company announced June 13
You may also be interested in...
Pharmion’s Vidaza Approved For IV Administration
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.
Pharmion’s Vidaza Approved For IV Administration
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.
Pharmion Vidaza To Be Launched By July 1 For Bone Marrow Disorder
Approval comes more than a month before FDA’s June 29 action date for azacitidine.